6.76CHF
977.57 MCHF
7.93 BCHF
144.19 M
About BIOGEN IDEC
Sector
CEO
Christopher A. Viehbacher
Headquarters
Cambridge
Website
Employees (FY)
7.57 K
Founded
1978
ISIN
US09062X1037
FIGI
BBG006TLND59
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where BIIB is featured.
Frequently Asked Questions
The current price of BIIB is 232.00 CHF — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on SIX exchange BIOGEN IDEC stocks are traded under the ticker BIIB.
BIOGEN IDEC is going to release the next earnings report on Apr 24, 2024. Keep track of upcoming events with our Earnings Calendar.
BIIB stock is 0% volatile and has beta coefficient of 0.74. Check out the list of the most volatile stocks — is BIOGEN IDEC there?
One year price forecast for BIOGEN IDEC has a max estimate of 358.26 CHF and a min estimate of 194.17 CHF.
BIIB earnings for the last quarter are 3.99 CHF whereas the estimation was 3.64 CHF which accounts for 9.73% surprise. Estimated earnings for the next quarter are 2.68 CHF. See more details about BIOGEN IDEC earnings.
BIOGEN IDEC revenue for the last quarter amounts to 2.32 B CHF despite the estimated figure of 2.20 B CHF. In the next quarter revenue is expected to reach 2.08 B CHF.
Yes, you can track BIOGEN IDEC financials in yearly and quarterly reports right on TradingView.
BIIB net income for the last quarter is 210.23 M CHF, while the quarter before that showed −62.35 M CHF of net income which accounts for 437.20% change. Track more BIOGEN IDEC financial stats to get the full picture.
Today BIOGEN IDEC has the market capitalization of 25.50 B, it has increased by 1.26% over the last week.
No, BIIB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BIIB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOGEN IDEC stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 7.57 K employees. See our rating of the largest employees — is BIOGEN IDEC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOGEN IDEC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOGEN IDEC stock shows the sell signal. See more of BIOGEN IDEC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on BIOGEN IDEC future price: according to them, BIIB price has a max estimate of 358.26 CHF and a min estimate of 194.17 CHF. Read a more detailed BIOGEN IDEC forecast: see what analysts think of BIOGEN IDEC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOGEN IDEC EBITDA is 1.79 B CHF, and current EBITDA margin is 22.58%. See more stats in BIOGEN IDEC financial statements.